Recent Analysts’ Ratings Updates for Phreesia (PHR)

A number of research firms have changed their ratings and price targets for Phreesia (NYSE: PHR):

• 2/8/2026 – Phreesia was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 2/4/2026 – Phreesia was given a new $22.00 price target on by analysts at Mizuho.
• 1/31/2026 – Phreesia was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 1/28/2026 – Phreesia had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 1/23/2026 – Phreesia had its price target lowered by analysts at DA Davidson from $35.00 to $30.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Phreesia had its price target lowered by analysts at Citigroup Inc. from $29.00 to $25.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Phreesia is now covered by analysts at Royal Bank Of Canada. They set a “moderate buy” rating and a $26.00 price target on the stock.
• 1/8/2026 – Phreesia is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.
• 1/8/2026 – Phreesia was given a new $24.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Phreesia is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.
• 1/6/2026 – Phreesia was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.

Insider Buying and Selling

In other Phreesia news, insider David Linetsky sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $103,863.06. Following the sale, the insider owned 231,723 shares in the company, valued at $3,941,608.23. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Evan Roberts sold 6,317 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $107,452.17. Following the completion of the transaction, the insider owned 834,632 shares of the company’s stock, valued at $14,197,090.32. The trade was a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 60,766 shares of company stock worth $1,013,817. 5.50% of the stock is owned by company insiders.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.